Gradient Investments’s Royalty Pharma RPRX Stock Holding History

Gradient Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-19	Closed	-$501	–	1060
2024 Q2	$501	Buy	+19	New	+$527	﹤0.01%	1185

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gradient Investments's RPRX Position: Q3 2024 in Review

Gradient Investments sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 19 shares — an estimated $501 sold.

Gradient Investments first reported a position in RPRX in Q2 2024 and held it in 1 quarter. The position peaked at $501 in Q2 2024. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

Gradient Investments reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
Gradient Investments sold 19 Royalty Pharma shares in Q3 2024, an estimated $501.
Gradient Investments first reported a position in Royalty Pharma in Q2 2024 and held it in 1 quarter.
Gradient Investments's Royalty Pharma position peaked at $501 in Q2 2024.
395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Gradient Investments's 13F filing for Q3 2024, filed 15 Oct 2024.